BeOne’s sonrotoclax gains priority FDA review for mantle cell lymphoma

Sonrotoclax has also secured breakthrough therapy status from the US regulator for R/R mantle cell lymphoma in adults. Credit: MY STOCKERS/Shutterstock.com.



  • BeOne FDA review